Navigation Links
Reiner in Medical News

Rice U. conference to explore music's role in human cognition and behavior

...er speakers will be Jonathan Berger, co-director of the Stanford Institute for Creativity and the Arts at Stanford University; Fred Lerdahl, the Fritz reiner Professor of Music Composition at Columbia University; Sarah Rothenberg, renowned pianist and artistic director of Da Camera of Houston; Gottfried Sch...

New Heart Disease Markers Discovered

...cs also play a role -- accounting for about 40 percent elevated CRP levels, reiner said. "The genetic side of this is rather straightforward," explained Dr... levels; researchers wanted to find the other players. In separate efforts, reiner and Ridker led research teams to see if they could locate them. Using ge...
Reiner in Medical Technology

BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine

...the cancer therapy field, the company has, for a minor payment, acquired from Pharmexa the families of patents that it had previously licensed. reiner Laus, MD, President & CEO of BN ImmunoTherapeutics, said: "I am pleased that we once again can confirm the unique safety profile of MVA-BN(R) and ...

BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

... warrant confirmation with a Phase III study and when confirmed this product has the potential to fulfill an unmet medical need for these patients." reiner Laus, President and Chief Executive Officer, BN ImmunoTherapeutics, said "We are delighted with these promising results from this Phase II study, whic...

Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

...r Aamund Chairman Conference call A conference call will be held today, 7 October 2008 at 10:30 am (CEST). Anders Hedegaard, President & CEO and reiner Laus MD and CEO of BN ImmunoTherapeutics Inc. will present. The accompanying presentation will be available on the company's website: http://www.bava...

BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine

...st cancer, in the top three cancer market, each with more than 500,000 new diagnosed incidents globally per year and only limited treatment options. reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The initiation of clinical studies with our therapeutic prostate cancer vaccine advances our...
Reiner in Medical Products

Androstanediol Glucuronide RIA Test

Description:...Rittmaster RS. Endocrin Rev 14:121-132, 1993. 2. Dorfman RI & Shipley RA. Androgens. John Wiley and Sons, Inc., New York, 1956, pp.116-128. 3. reiner BJ, et al. J Clin Endocrinol and Metab 69:105-109, 1989. 4. Pang S, et al. J Clin Endocrinol Metab 73:166-174, 1991. 5. Horton R & Lobo RA. Cl...
Company:Diagnostic Systems Laboratories, Inc.

Androstanediol Glucuronide EIA Test

Description:...Rittmaster RS. Endocrin Rev 14:121-132, 1993. 2. Dorfman RI & Shipley RA. Androgens. John Wiley and Sons, Inc., New York, 1956, pp.116-128. 3. reiner BJ, et al. J Clin Endocrinol and Metab 69:105-109, 1989. 4. Pang S, et al. J Clin Endocrinol Metab 73:166-174, 1991. 5. Horton R & Lobo RA. Cl...
Company:Diagnostic Systems Laboratories, Inc.
Reiner in Biological News

Weizmann Institute scientists show extra copies of a gene carry extra risk

... mentally retarded. But new research by Prof. Orly reiner of the Institute's Molecular Genetics Department, ...ng extra LIS1 genes can cause problems as well. reiner was the first to discover LIS1's tie to lissenceph...us factors in the cell became more disordered. reiner then asked whether their findings might apply to h...

More freedom to take risks: DFG funds the first Reinhart Koselleck Projects

...means of a special funding programme focussing on the field. Prof. Dr. reiner Kirchheim (65), materials science, professor at the Institute of Material P...versity of Gttingen By taking an experimental and theoretical approach, reiner Kirchheim aims to demonstrate that the well-known effect of surface-active ...
Reiner in Biological Technology

BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)

... Further detailed results on PROSTVAC(TM) will be presented at the 2009 ASCO Annual Meeting on May 29 -June 2, 2009 in Orlando, Florida. reiner Laus, MD, President & CEO of BN ImmunoTherapeutics, said: "We are proud that for the first time since obtaining an exclusive license from the NIH,...

BN ImmunoTherapeutics Announces Partnership With National Cancer Institute

...ative effort between BN ImmunoTherapeutics and NCI will hopefully provide urgently needed new therapies for patients suffering from prostate cancer. reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The NCI relationship opens up for us new and exciting opportunities within the field of canc...

Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process

...ously amongst others he worked as Finance Director at Berlingske Tidende. reiner Laus, MD., President & CEO of Bavarian Nordic's US subsidiary, BN ImmunoThe...Andersen, EVP Commercial Affairs Paul Chaplin, EVP Research & Development reiner Laus, EVP, and CEO of BN ImmunoTherapeutics Inc. Morten Max Rasmussen, EVP...
Reiner in Biological Dictionary

Monocytes

... iron was released from the monocytes in the form of ferritin, Hb, and as ... The kinetics of iron release were identical for HH monocytes . ... reiner mentions three ways that monocytes and macrophages can be de- activated, ... Endothelial infection by Yersinia-infected monocytes has been documen...
Other Tags
(Date:8/3/2015)... , ... August 03, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today welcomed the ... for review OPKO’s New Drug Application for a new treatment for chronic kidney ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... today that Joe Williams has joined its growing California employee benefits division. ... service model to his clients. Mr. Williams will be joining the newly integrated ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
Other Contents